<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41021739</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1522-1555</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Sep</Month><Day>29</Day></PubDate></JournalIssue><Title>American journal of physiology. Endocrinology and metabolism</Title><ISOAbbreviation>Am J Physiol Endocrinol Metab</ISOAbbreviation></Journal><ArticleTitle>Effect of a Low Volume Exercise Intervention on the Plasma Lipidome in People with Normal Glucose, Prediabetes or Type 2 Diabetes: A Randomised Controlled Trial.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1152/ajpendo.00171.2025</ELocationID><Abstract><AbstractText>High-intensity interval training (HIIT) may improve metabolic outcomes in people with type 2 diabetes (T2D) and prediabetes (PD). This randomised controlled trial assessed plasma lipidomic differences between overweight participants (BMI&gt;25 kg/m<sup>2</sup>) with normal glucose tolerance (NGT) (n=74), PD (n=60) or newly-diagnosed T2D (n=26), and the effects of a combined HIIT and progressive resistance training (PRT) intervention on circulating lipids. Participants were randomized to either a stretching or HIIT+PRT protocol. Fasted plasma was collected at baseline and after 12-weeks. Plasma lipids, D- and L-serine, and D- and L-alanine, were quantified with liquid chromatography-tandem mass spectrometry. Plasma lipidomics revealed significantly lower levels of sphingomyelin and lysophosphatidylcholine (LPC) and higher diacylglycerol and deoxyceramide species in T2D compared to NGT or PD. The HIIT+PRT intervention significantly reduced circulating deoxyceramides in the T2D group. We investigated the basis for elevated atypical deoxyceramides in T2D, which utilise L-alanine rather than L-serine as biosynthetic substrates. Serine levels were unchanged; however, L-alanine and D-alanine were increased in T2D. Total diacylglycerol, L-alanine and D-alanine positively correlated with fasting glucose, insulin, Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), glycated hemoglobin and liver fat, whereas sphingomyelin and LPC inversely correlated with fasting glucose and HOMA-IR. The L-alanine:L-serine ratio positively correlated with deoxyceramide levels, but was unaltered by the HIIT+PRT intervention. This study reveals plasma lipidomic perturbations in T2D, establishing that excess L-alanine may underpin elevated metabolically-adverse deoxyceramide levels in T2D, and demonstrates that a 12-week HIIT+PRT protocol significantly reduces deoxyceramides in individuals with T2D independently of the plasma L-alanine:L-serine ratio.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Marian</LastName><ForeName>Oana C</ForeName><Initials>OC</Initials><Identifier Source="ORCID">0000-0001-5629-7884</Identifier><AffiliationInfo><Affiliation>Greg Brown Diabetes &amp; Endocrine Research Laboratory, Charles Perkins Centre, The University of Sydney, NSW, 2006, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, NSW, 2006, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Min</LastName><ForeName>Danqing</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-2576-4344</Identifier><AffiliationInfo><Affiliation>Greg Brown Diabetes &amp; Endocrine Research Laboratory, Charles Perkins Centre, The University of Sydney, NSW, 2006, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Central Clinical School, Faculty of Medicine and Health, The University of Sydney, NSW, 2006, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Endocrinology, Royal Prince Alfred Hospital, NSW, 2050, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baker</LastName><ForeName>Callum J</ForeName><Initials>CJ</Initials><Identifier Source="ORCID">0000-0002-7818-8440</Identifier><AffiliationInfo><Affiliation>Greg Brown Diabetes &amp; Endocrine Research Laboratory, Charles Perkins Centre, The University of Sydney, NSW, 2006, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Central Clinical School, Faculty of Medicine and Health, The University of Sydney, NSW, 2006, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Health Sciences, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hodgkins</LastName><ForeName>Christopher John</ForeName><Initials>CJ</Initials><Identifier Source="ORCID">0000-0002-0210-6410</Identifier><AffiliationInfo><Affiliation>School of Life and Environmental Sciences, The University of Sydney, NSW, 2006, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gerofi</LastName><ForeName>James</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-4633-4482</Identifier><AffiliationInfo><Affiliation>Greg Brown Diabetes &amp; Endocrine Research Laboratory, Charles Perkins Centre, The University of Sydney, NSW, 2006, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Central Clinical School, Faculty of Medicine and Health, The University of Sydney, NSW, 2006, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xiaoyu</ForeName><Initials>X</Initials><Identifier Source="ORCID">0009-0000-3800-3619</Identifier><AffiliationInfo><Affiliation>Greg Brown Diabetes &amp; Endocrine Research Laboratory, Charles Perkins Centre, The University of Sydney, NSW, 2006, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Central Clinical School, Faculty of Medicine and Health, The University of Sydney, NSW, 2006, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Nathan Anthony</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>Boden Initiative, Charles Perkins Centre, The University of Sydney, NSW, 2006, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine and Health, The University of Sydney, NSW, 2006, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Don</LastName><ForeName>Anthony S</ForeName><Initials>AS</Initials><Identifier Source="ORCID">0000-0003-1655-1184</Identifier><AffiliationInfo><Affiliation>School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, NSW, 2006, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Twigg</LastName><ForeName>Stephen M</ForeName><Initials>SM</Initials><Identifier Source="ORCID">0000-0002-2681-8201</Identifier><AffiliationInfo><Affiliation>Greg Brown Diabetes &amp; Endocrine Research Laboratory, Charles Perkins Centre, The University of Sydney, NSW, 2006, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Central Clinical School, Faculty of Medicine and Health, The University of Sydney, NSW, 2006, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Endocrinology, Royal Prince Alfred Hospital, NSW, 2050, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>1113612</GrantID><Agency>NHMRC of Australia</Agency><Country/></Grant><Grant><GrantID>G179502</GrantID><Agency>University of Sydney DVC Research COVID-19</Agency><Country/></Grant><Grant><GrantID>G217365</GrantID><Agency>Reginal Ward and Adrian Cotter Foundation</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Physiol Endocrinol Metab</MedlineTA><NlmUniqueID>100901226</NlmUniqueID><ISSNLinking>0193-1849</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Deoxyceramides</Keyword><Keyword MajorTopicYN="N">Diabetes</Keyword><Keyword MajorTopicYN="N">Exercise</Keyword><Keyword MajorTopicYN="N">Lipidomics</Keyword><Keyword MajorTopicYN="N">Prediabetes</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>29</Day><Hour>22</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>29</Day><Hour>22</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>29</Day><Hour>14</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41021739</ArticleId><ArticleId IdType="doi">10.1152/ajpendo.00171.2025</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>